Johnson & Johnson (NYSE:JNJ) Shares Sold by Nachman Norwood & Parrott Inc

Nachman Norwood & Parrott Inc lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,106 shares of the company’s stock after selling 704 shares during the quarter. Johnson & Johnson comprises approximately 0.9% of Nachman Norwood & Parrott Inc’s investment portfolio, making the stock its 23rd largest holding. Nachman Norwood & Parrott Inc’s holdings in Johnson & Johnson were worth $6,716,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of JNJ. Winslow Evans & Crocker Inc. increased its holdings in shares of Johnson & Johnson by 0.3% in the second quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock valued at $3,037,000 after purchasing an additional 69 shares during the period. Lathrop Investment Management Corp grew its holdings in Johnson & Johnson by 1.4% in the second quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock valued at $689,000 after purchasing an additional 69 shares during the last quarter. Reik & CO. LLC grew its holdings in Johnson & Johnson by 0.4% in the second quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock valued at $2,493,000 after purchasing an additional 70 shares during the last quarter. Old North State Trust LLC lifted its position in shares of Johnson & Johnson by 0.5% in the second quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock valued at $1,922,000 after acquiring an additional 71 shares in the last quarter. Finally, Delta Investment Management LLC lifted its position in Johnson & Johnson by 1.0% during the second quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock worth $1,041,000 after buying an additional 71 shares during the period. Institutional investors own 67.44% of the company’s stock.

A number of research analysts have commented on the company. Bank of America reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. Raymond James increased their target price on Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $161.00 to $164.00 in a report on Monday, July 20th. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $164.93.

Shares of JNJ stock opened at $148.10 on Friday. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The stock has a market cap of $389.92 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The business’s fifty day moving average is $148.57 and its 200-day moving average is $146.59. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The company had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. During the same period last year, the firm earned $2.12 EPS. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 8 earnings per share for the current year.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: Discover Your Risk Tolerance

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.